153 related articles for article (PubMed ID: 14962263)
1. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
3. Modern management of myelofibrosis.
Cervantes F
Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
[TBL] [Abstract][Full Text] [Related]
4. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
5. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
6. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
8. [Splenectomy in 5 patients with idiopathic myelofibrosis].
Nozato A; Mizorogi F; Fukumi S; Watanabe H; Kobayashi M
Rinsho Ketsueki; 2001 Aug; 42(8):627-32. PubMed ID: 11579502
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
10. New and old treatment modalities in primary myelofibrosis.
Cervantes F; Mesa R; Barosi G
Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
[TBL] [Abstract][Full Text] [Related]
11. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
12. [Advances in thalidomide therapy for idiopathic myelofibrosis].
Song L; Chen JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):651-3. PubMed ID: 19968089
[TBL] [Abstract][Full Text] [Related]
13. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
[TBL] [Abstract][Full Text] [Related]
19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
20. Low-dose thalidomide in myelofibrosis.
Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
